A new study examined whether routine blood test measures could help in identifying disease flares in people with systemic ...

A recent review published in Current Molecular Pharmacology explores the therapeutic potential of melatonin in systemic lupus ...

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were ...

A common virus carried by most humans could trigger lupus, offering new clues for preventing and treating this dangerous ...

About 5 million people worldwide live with the autoimmune condition lupus. This condition can cause a range of symptoms, including tiredness, fever, joint pain and a characteristic butterfly-shaped ...

Patients with systemic lupus erythematosus and diabetes who received sodium-glucose cotransporter 2 inhibitors exhibited ...

Dermatologists long reluctant to tackle cutaneous lupus erythematosus may be more open to treating patients with approvals ...

InnoCare Pharma (INCPF) announced that the phase IIb clinical study of novel BTK inhibitor orelabrutinib has met the primary endpoint in patients ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.